Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says
Executive Summary
Bristol-Myers Squibb/AstraZeneca’s type 2 diabetes treatment Onglyza (saxagliptin) has been chosen as the focus of the first drug evaluation in the mini-Sentinel active safety surveillance project in part because observational findings on the drug can be compared to a large Phase IV clinical trial now under way.
You may also be interested in...
Mini-Sentinel Expanding Drug Safety Efforts To Prospective Surveillance
The effort will complement the FDA-funded project’s existing ability to retrospectively measure exposure to products and then analyze specific adverse outcomes.
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
The Mini-Sentinel medical products safety surveillance project will assess the health impact of FDA-mandated label warnings for use of long-acting beta agonists in asthma, Harvard Pilgrim Health Care Institute’s Richard Platt noted during a Sept. 15 webinar on Mini-Sentinel sponsored by the Brookings Institution.
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
The Mini-Sentinel medical products safety surveillance project will assess the health impact of FDA-mandated label warnings for use of long-acting beta agonists in asthma, Harvard Pilgrim Health Care Institute’s Richard Platt noted during a Sept. 15 webinar on Mini-Sentinel sponsored by the Brookings Institution.